Brown Advisory’s Celldex Therapeutics CLDX Stock Holding History

Brown Advisory’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,723	Closed	-$221K	–	1139
2021 Q4	$221K	Buy	+5,723	New	+$249K	﹤0.01%	1145

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Brown Advisory's CLDX Position: Q1 2022 in Review

Brown Advisory sold out of Celldex Therapeutics (CLDX) in Q1 2022, closing a stake of 5,723 shares — an estimated $221K sold.

Brown Advisory first reported a position in CLDX in Q4 2021 and held it in 1 quarter. The position peaked at $221K in Q4 2021. 168 funds tracked by Wall St. Rank hold CLDX as of Q1 2022.

Brown Advisory reported no remaining Celldex Therapeutics position as of Q1 2022 after selling out during the quarter.
Brown Advisory sold 5,723 Celldex Therapeutics shares in Q1 2022, an estimated $221K.
Brown Advisory first reported a position in Celldex Therapeutics in Q4 2021 and held it in 1 quarter.
Brown Advisory's Celldex Therapeutics position peaked at $221K in Q4 2021.
168 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2022.

Based on Brown Advisory's 13F filing for Q1 2022, filed 9 May 2022.